Skip Navigation Links
Skip Navigation Links


MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.  EAY131 (NCT02465050)  (MBMC Contact: Missy Kuhn 314-996-5868) 

Randomized Phase III trial of mematine and whole-brain radiotherapy with or without hippocampal avoidance in patients with brain metastases  NRG-CC001 (NCT02360215 )  (MBMC Contact:  Diana Christian 314-996-5888)  (Requires radiation oncologist to undergo training and specialized MRIs - approved at MBMC)

Randomized Phase III Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression Versus Ipilimumab + Nivolumab follwed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma  EA6134 (NCT02224781)  (MBMC Contact: Missy Kuhn 314-996-5868)

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot be Removed by Surgery  (Dabrafenib and Trametinib Provided) SWOG S1320 (NCT02196181)  (MBMC Contact: Missy Kuhn 314-996-5868)

Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versis nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma
 ECOG-ACRIN EA6141  (NCT02339571)   (MBMC Contact:  Missy Kuhn 314-996-5868 Accrual suspended effective 6/23/17.

Lymphoma Cancer Trials in St. Louis, MO

All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy